CLS receives new order for single use products from UTMB in the U.S., for treatment of early stage prostate cancer
Clinical Laserthermia Systems (CLS) (publ), has, through its subsidiary CLS Americas Inc., received yet another order for for CLS’s sterile single use products, for MRI-guided focal laser ablation, from the University of Texas Medical Branch (UTMB). The order value amounts to about 400 000 SEK.
- UTMB continues to choose our products for treatment of patients with early stage prostate cancer, or other tumor disease, in the prostate. UTMB has become an important reference for us in the USA-market and the collaboration with the hospital continues to develop in a positive way, says Dan Mogren, CCO at CLS.
In October 2017 CLS entered into a supplier agreement with UTMB and with this UTMB placed a first order for CLS’ single use accessories for MRI guided laser ablation. Thereafter UTMB has put in additional orders for single use products and also bought Mobile Laser Unit and can now work with a complete TRANBERG®|Thermal Therapy System.
CLS estimates the total addressable market (USA/EU/Japan) for focal laser ablation of benign prostatic hyperplasia (BPH) and malign localized prostate cancer to amount to about 500 000 treatments yearly.
More about University of Texas Medical Branch: www.utmb.edu
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Ph: +46 – (0)702 – 90 33 00 E-mail: firstname.lastname@example.org
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se